FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis

Author profile image Aggregator
0 comments
Cemdisiran (Livsayis), Regeneronโ€™s complement C5-directed siRNA dosed four times a year, can now treat adults in the US who have AChR-antibody-positive generalized myasthenia gravis.

Source: NeurologyLive Published 18 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article